Croda International Plc (LON:CRDA) Insider Steve Foots Buys 5 Shares

Croda International Plc (LON:CRDA) insider Steve Foots purchased 5 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was bought at an average cost of GBX 3,203 ($41.24) per share, with a total value of £160.15 ($206.19).

Steve Foots also recently made the following trade(s):

• On Monday, February 10th, Steve Foots acquired 5 shares of Croda International stock. The stock was purchased at an average price of GBX 3,094 ($39.84) per share, for a total transaction of £154.70 ($199.18).
• On Friday, January 10th, Steve Foots bought 5 shares of Croda International stock. The shares were purchased at an average price of GBX 3,272 ($42.13) per share, with a total value of £163.60 ($210.63).

Croda International Trading Down 2.6 %

Croda International stock traded down GBX 84 ($1.08) during mid-day trading on Tuesday, hitting GBX 3,088 ($39.76). The stock had a trading volume of 64,458,609 shares, compared to its average volume of 3,656,637. The stock has a 50-day simple moving average of GBX 3,247.20 and a two-hundred day simple moving average of GBX 3,580.63. The company has a current ratio of 2.72, a quick ratio of 2.25 and a debt-to-equity ratio of 30.90. The stock has a market capitalization of £4.32 billion, a PE ratio of 26.54, a P/E/G ratio of 1.40 and a beta of 0.74. Croda International Plc has a 12 month low of GBX 3,025.90 ($38.96) and a 12 month high of GBX 5,124 ($65.97).

Croda International (LON:CRDA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported GBX 142.60 ($1.84) EPS for the quarter. Croda International had a net margin of 9.98% and a return on equity of 6.96%. As a group, sell-side analysts forecast that Croda International Plc will post 181.8307268 EPS for the current year.

Croda International Company Profile

Founded in 1925 with the aim of turning bio-based raw materials into innovative ingredients, Croda International is a speciality chemicals company focused on consumer care and life sciences markets. The company is focused on creating, making and selling innovative ingredients that deliver real benefits to a diverse range of customers and employs more than 6,000 people around the world.